FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4210346061> ?p ?o ?g. }

• W4210346061 endingPage "14" @default.
• W4210346061 startingPage "4" @default.
• W4210346061 abstract "The aims of this study are to describe the use of pharmaceutical venous thromboembolism (pVTE) prophylaxis in patients with traumatic brain injury (TBI) in Europe and study the association of pVTE prophylaxis with outcome. We included 2006 patients ≥18 years of age admitted to the intensive care unit from the CENTER-TBI study. VTE events were recorded based on clinical symptoms. Variation between 54 centers in pVTE prophylaxis use was assessed with a multi-variate random-effect model and quantified with the median odds ratio (MOR). The association between pVTE prophylaxis and outcome (Glasgow Outcome Scale-Extended at 6 months) was assessed at center level with an instrumental variable analysis and at patient level with a multi-variate proportional odds regression analysis and a propensity-matched analysis. A time-dependent Cox survival regression analysis was conducted to determine the effect of pVTE prophylaxis on survival during hospital stay. The association between VTE prophylaxis and computed tomography (CT) progression was assessed with a logistic regression analysis. Overall, 56 patients (2%) had a VTE during hospital stay. The majority, 1279 patients (64%), received pVTE prophylaxis, with substantial between-center variation (MOR, 2.7; p < 0.001). A moderate association with improved outcome was found at center level (odds ratio [OR], 1.2 [0.7-2.1]) and patient level (multi-variate adjusted OR, 1.4 [1.1-1.7], and propensity adjusted OR, 1.5 [1.1-2.0]), with similar results in subgroup analyses. Survival was higher with the use of pVTE prophylaxis (p < 0.001). We found no clear effect on CT progression (OR, 0.9; CI [0.6-1.2]). Overall, practice policies for pVTE prophylaxis vary substantially between European centers, whereas pVTE prophylaxis may contribute to improved outcome. Trial registration number is NCT02210221 at ClinicalTrials.gov, registered on August 6, 2014 (first patient enrollment on December 19, 2014)." @default.
• W4210346061 created "2022-02-08" @default.
• W4210346061 creator A5026542917 @default.
• W4210346061 creator A5026647662 @default.
• W4210346061 creator A5046564023 @default.
• W4210346061 creator A5051621488 @default.
• W4210346061 creator A5057778218 @default.
• W4210346061 creator A5057793733 @default.
• W4210346061 creator A5076856368 @default.
• W4210346061 creator A5083980961 @default.
• W4210346061 creator A5088222616 @default.
• W4210346061 creator A5091435927 @default.
• W4210346061 date "2022-01-01" @default.
• W4210346061 modified "2023-10-18" @default.
• W4210346061 title "Pharmaceutical Venous Thrombosis Prophylaxis in Critically Ill Traumatic Brain Injury Patients" @default.
• W4210346061 cites W1833381290 @default.
• W4210346061 cites W1969135321 @default.
• W4210346061 cites W1977330056 @default.
• W4210346061 cites W2001491502 @default.
• W4210346061 cites W2018777522 @default.
• W4210346061 cites W2034832518 @default.
• W4210346061 cites W2046700467 @default.
• W4210346061 cites W2066450038 @default.
• W4210346061 cites W2117784915 @default.
• W4210346061 cites W2125568432 @default.
• W4210346061 cites W2137120787 @default.
• W4210346061 cites W2522738478 @default.
• W4210346061 cites W2562481671 @default.
• W4210346061 cites W2586825713 @default.
• W4210346061 cites W2793117751 @default.
• W4210346061 cites W2883545209 @default.
• W4210346061 cites W2972355048 @default.
• W4210346061 cites W3040371077 @default.
• W4210346061 cites W4211043869 @default.
• W4210346061 doi "https://doi.org/10.1089/neur.2021.0037" @default.
• W4210346061 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35112104" @default.
• W4210346061 hasPublicationYear "2022" @default.
• W4210346061 type Work @default.
• W4210346061 citedByCount "2" @default.
• W4210346061 countsByYear W42103460612022 @default.
• W4210346061 crossrefType "journal-article" @default.
• W4210346061 hasAuthorship W4210346061A5026542917 @default.
• W4210346061 hasAuthorship W4210346061A5026647662 @default.
• W4210346061 hasAuthorship W4210346061A5046564023 @default.
• W4210346061 hasAuthorship W4210346061A5051621488 @default.
• W4210346061 hasAuthorship W4210346061A5057778218 @default.
• W4210346061 hasAuthorship W4210346061A5057793733 @default.
• W4210346061 hasAuthorship W4210346061A5076856368 @default.
• W4210346061 hasAuthorship W4210346061A5083980961 @default.
• W4210346061 hasAuthorship W4210346061A5088222616 @default.
• W4210346061 hasAuthorship W4210346061A5091435927 @default.
• W4210346061 hasBestOaLocation W42103460611 @default.
• W4210346061 hasConcept C118552586 @default.
• W4210346061 hasConcept C126322002 @default.
• W4210346061 hasConcept C151956035 @default.
• W4210346061 hasConcept C156957248 @default.
• W4210346061 hasConcept C167135981 @default.
• W4210346061 hasConcept C17923572 @default.
• W4210346061 hasConcept C187960798 @default.
• W4210346061 hasConcept C2776376669 @default.
• W4210346061 hasConcept C2780011451 @default.
• W4210346061 hasConcept C2780110798 @default.
• W4210346061 hasConcept C2780868729 @default.
• W4210346061 hasConcept C2781017439 @default.
• W4210346061 hasConcept C44249647 @default.
• W4210346061 hasConcept C50382708 @default.
• W4210346061 hasConcept C71924100 @default.
• W4210346061 hasConceptScore W4210346061C118552586 @default.
• W4210346061 hasConceptScore W4210346061C126322002 @default.
• W4210346061 hasConceptScore W4210346061C151956035 @default.
• W4210346061 hasConceptScore W4210346061C156957248 @default.
• W4210346061 hasConceptScore W4210346061C167135981 @default.
• W4210346061 hasConceptScore W4210346061C17923572 @default.
• W4210346061 hasConceptScore W4210346061C187960798 @default.
• W4210346061 hasConceptScore W4210346061C2776376669 @default.
• W4210346061 hasConceptScore W4210346061C2780011451 @default.
• W4210346061 hasConceptScore W4210346061C2780110798 @default.
• W4210346061 hasConceptScore W4210346061C2780868729 @default.
• W4210346061 hasConceptScore W4210346061C2781017439 @default.
• W4210346061 hasConceptScore W4210346061C44249647 @default.
• W4210346061 hasConceptScore W4210346061C50382708 @default.
• W4210346061 hasConceptScore W4210346061C71924100 @default.
• W4210346061 hasIssue "1" @default.
• W4210346061 hasLocation W42103460611 @default.
• W4210346061 hasLocation W42103460612 @default.
• W4210346061 hasLocation W42103460613 @default.
• W4210346061 hasLocation W42103460614 @default.
• W4210346061 hasOpenAccess W4210346061 @default.
• W4210346061 hasPrimaryLocation W42103460611 @default.
• W4210346061 hasRelatedWork W1493666455 @default.
• W4210346061 hasRelatedWork W2010414248 @default.
• W4210346061 hasRelatedWork W2160868159 @default.
• W4210346061 hasRelatedWork W2317759596 @default.
• W4210346061 hasRelatedWork W2735453587 @default.
• W4210346061 hasRelatedWork W2912359563 @default.
• W4210346061 hasRelatedWork W2912909642 @default.
• W4210346061 hasRelatedWork W2924308016 @default.
• W4210346061 hasRelatedWork W3007385212 @default.

• next